Modulo Bio develops therapeutics that target microglial cells to treat neurological conditions. Their technology identifies specific microglial behaviors that support and restore brain health by analyzing common signals across various neuroimmune system models. The company focuses on creating drugs that enhance the neuroimmune system for therapeutic intervention.
Funding
$17.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neurodegenerative disorders often fail to address the underlying neuroinflammation and immune dysregulation that contribute to disease progression. Traditional approaches may not effectively target the brain's unique immune cells, called microglia, which play a critical role in neuronal health and disease pathology. This can lead to limited efficacy and a failure to halt or reverse the course of debilitating conditions like Alzheimer's and Parkinson's.
Solution
Modulo Bio is developing targeted immunotherapies designed to reprogram the brain's immune system and restore neuronal function in patients with neurodegenerative diseases. Their approach focuses on modulating microglial behavior to promote neuroprotection and resolve neuroinflammation. By combining stem cell engineering, neurobiology, multiomics, and machine learning, Modulo Bio identifies and enhances microglial behaviors that support brain health. This hybrid approach enables the development of drugs that target specific microglial pathways, offering a novel strategy for treating neurological conditions.
Target Audience
The primary target audience includes patients suffering from neurodegenerative disorders such as Alzheimer's, Parkinson's, Frontotemporal Dementia (FTD), and Amyotrophic Lateral Sclerosis (ALS), as well as pharmaceutical companies and research institutions focused on neuroimmunology.
Features
- Utilizes stem cell engineering to rapidly generate human microglia-centered neuroimmune microenvironments with neurons and astrocytes.
- Employs multiple complementary models of the neuroimmune system to identify key signals and separate them from noise.
- Leverages CRISPR and single-cell techniques to manipulate and measure the neuroimmune system in cell models and patient samples.
- Applies machine learning to discover cell fingerprints, functional biomarkers, optimal experiments, and biological relationships.
- Developing a CSF1R inhibitor for Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS).